[
    {
        "file_name": "EtonPharmaceuticalsInc_20191114_10-Q_EX-10.1_11893941_EX-10.1_Development Agreement.pdf",
        "perturbation": [
            {
                "type": "Structural Flaws - In Text Contradiction",
                "original_text": "11.1 Term. The term of this Agreement shall automatically become effective upon the occurrence of (i) ETON executing a commercial\nsupply agreement with a contract manufacturing organization within forty-five (45) days of the Execution Date, provided that ETON has exercised\nbest efforts to execute such agreement and the failure to execute is solely caused by the refusal or inability of the proposed manufacturing\norganization to sign a reasonable agreement; and (ii) acceptance for review of the Dossier or marketing application for [ * * * ] by the FDA no later\nthan September 2, 2019 (such date, the “Effective Date”) and shall end upon the termination or expiration of the Agreement as set forth in Section\n11 (the “Term”). For avoidance of doubt, all rights conferred to ETON under this Agreement for the purpose of allowing ETON to Market the\nProduct in the Territory shall continue until a Party terminates this Agreement. Aucta should continue to receive 15% of Net Sales Royalty for as\nlong as ETON is selling the Product(s) in the Territory, unless otherwise agreed to under this Agreement. The obligations of ETON to consummate\nthe transactions contemplated by this Agreement shall be subject to the fulfillment or ETON’s waiver of the occurrence of the Effective Date.",
                "changed_text": "11.1 Term. The term of this Agreement shall automatically become effective upon the occurrence of (i) ETON executing a commercial\nsupply agreement with a contract manufacturing organization within forty-five (45) days of the Execution Date, provided that ETON has exercised\nbest efforts to execute such agreement and the failure to execute is solely caused by the refusal or inability of the proposed manufacturing\norganization to sign a reasonable agreement; and (ii) acceptance for review of the Dossier or marketing application for [ * * * ] by the FDA no later\nthan September 2, 2019 (such date, the “Effective Date”) and shall end upon the termination or expiration of the Agreement as set forth in Section\n11 (the “Term”). For avoidance of doubt, all rights conferred to ETON under this Agreement for the purpose of allowing ETON to Market the\nProduct in the Territory shall cease immediately upon termination of this Agreement. Aucta may, at its sole discretion, allow ETON to continue to receive 15% of Net Sales Royalty for as\nlong as ETON is selling the Product(s) in the Territory, unless otherwise agreed to under this Agreement. The obligations of ETON to consummate\nthe transactions contemplated by this Agreement shall be subject to the fulfillment or ETON’s waiver of the occurrence of the Effective Date.",
                "explanation": "The original text states that Aucta *should* continue to receive 15% of Net Sales Royalty. The modified text alters this to state that Aucta *may, at its sole discretion* allow ETON to continue to receive 15% of Net Sales Royalty, creating an in-text contradiction.",
                "location": "Section 11.1"
            },
            {
                "type": "Structural Flaws - In Text Contradiction",
                "original_text": "12.2.6 it will not divest, sell, fail to maintain or otherwise dispose of any Dossier related to Products during the Term of this\nAgreement;",
                "changed_text": "12.2.6 it may divest, sell, fail to maintain or otherwise dispose of any Dossier related to Products during the Term of this\nAgreement given 60 days written notice;",
                "explanation": "The original text clearly states that Aucta *will not* divest, sell, fail to maintain or otherwise dispose of any Dossier related to Products during the Term of this Agreement. The modified text alters this to state that Aucta *may* divest given 60 days notice, creating an in-text contradiction.",
                "location": "Section 12.2.6"
            },
            {
                "type": "Structural Flaws - In Text Contradiction",
                "original_text": "13.1 Aucta’s Indemnification Obligations. Aucta shall indemnify, defend and hold ETON and its owners, officers, directors, Affiliates, and\nemployees (collectively, “ETON Indemnified Parties”) harmless from and against any and all Losses arising out of or resulting from any Third\nParty Claims made or suits brought against ETON Indemnified Parties which arise or result from (i) Aucta’s material breach of any of its\nrepresentations, warranties or covenants set forth in this Agreement, or any of its obligations hereunder; (ii) Aucta’s manufacture, registration,\nhandling, storage, use, transportation of any Product on or after the Effective Date, including, without limitation, any Claim for personal injury or\ndeath, to the extent such Third Party Claims arise from the period of time commencing on or after the Effective Date and to the extent such is not\nattributable to ETON’s breach of this Agreement or any Applicable Laws; or (iii) Aucta’s negligence or willful misconduct with regard to the\nProducts to the extent such is not attributable to ETON’s breach of this Agreement or any Applicable Laws.",
                "changed_text": "13.1 Aucta’s Indemnification Obligations. Aucta shall indemnify, defend and hold ETON and its owners, officers, directors, Affiliates, and\nemployees (collectively, “ETON Indemnified Parties”) harmless from and against any and all Losses arising out of or resulting from any Third\nParty Claims made or suits brought against ETON Indemnified Parties which arise or result from (i) Aucta’s material breach of any of its\nrepresentations, warranties or covenants set forth in this Agreement, or any of its obligations hereunder; (ii) Aucta’s manufacture, registration,\nhandling, storage, use, transportation of any Product on or after the Effective Date, including, without limitation, any Claim for personal injury or\ndeath, regardless of the Effective Date and even if attributable to ETON’s breach of this Agreement or any Applicable Laws; or (iii) Aucta’s negligence or willful misconduct with regard to the\nProducts whether attributable to ETON’s breach of this Agreement or any Applicable Laws.",
                "explanation": "The original text states the losses ETON faces arising out of certain situations is 'to the extent such is not attributable to ETON’s breach of this Agreement or any Applicable Laws'. The modified text removes the 'extent' and adds that the losses would be present regardless, creating an in-text contradiction.",
                "location": "Section 13.1"
            }
        ]
    }
]